STOCK TITAN
  1. Home
  2. News
  3. PDSB

PDS Biotechnology Corporation - PDSB STOCK NEWS

Welcome to our dedicated news page for PDS Biotechnology Corporation (Ticker: PDSB), a resource for investors and traders seeking the latest updates and insights on PDS Biotechnology Corporation.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect PDS Biotechnology Corporation's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of PDS Biotechnology Corporation's position in the market.

News
PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer
Rhea-AI Summary
PDS Biotech announces a Key Opinion Leader event to discuss positive, updated data from Phase 2 VERSATILE-002 clinical trial with Versamune® HPV in combination with KEYTRUDA® in recurrent or metastatic head and neck cancer. The event will focus on the trial results, unmet treatment needs in advanced head and neck cancer, and planned triple combination trial. The VERSATILE-002 trial evaluates Versamune® HPV with pembrolizumab in patients with unresectable, recurrent, or metastatic HPV16-positive HNSCC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.02%
Tags
conferences clinical trial
-
News
PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results
Rhea-AI Summary
PDS Biotechnology announces successful clinical trials with a 3-year survival rate of 75% in advanced head and neck cancer, leading to a focus on a triple combination treatment. The company reports strong safety profiles of its drugs and plans to start a pivotal randomized trial. Financially, PDS Biotech saw a net loss increase due to higher operating costs and interest expenses, despite a decrease in research and development expenses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.06%
Tags
earnings
-
News
PDS Biotechnology Announces Conference Call and Webcast for Business Update and Full Year 2023 Financial Results
Rhea-AI Summary
PDS Biotechnology (PDSB) will release financial results for the year ended December 31, 2023, and provide a business update on March 27, 2024. The company focuses on developing targeted cancer immunotherapies and infectious disease vaccines.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.56%
Tags
earnings
News
PDS Biotech Announces Publication of Preclinical Research and Grant of U.S. Composition of Matter Patent for Infectimune®
Rhea-AI Summary
PDS Biotechnology Corporation announces significant advancements in preclinical research and patent grants for its Infectimune® platform, showcasing improved CD4 T cell response and broad protection against influenza viruses. The company's innovative approach strengthens its position in developing targeted cancer immunotherapies and infectious disease vaccines.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.7%
Tags
clinical trial
-
News
PDS Biotech Announces Retirement of Lauren V. Wood, M.D., and Appointment of Kirk V. Shepard, M.D., as Chief Medical Officer
Rhea-AI Summary
PDS Biotechnology Corporation appoints Dr. Kirk V. Shepard as Chief Medical Officer, bringing over 30 years of experience in the pharmaceutical industry. Dr. Shepard's expertise will be crucial as the company transitions from clinical development research to regulatory strategy and commercialization for their lead targeted cancer immunotherapy candidates. The company also granted Dr. Shepard 200,000 stock options as a material inducement to his employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.03%
Tags
management
-
News
PDS Biotech to Participate at B. Riley Securities 4th Annual Oncology Conference
Rhea-AI Summary
PDS Biotechnology Corporation (PDSB) announced its participation in the B. Riley Securities 4th Annual Oncology Conference, where the President and CEO, Frank Bedu-Addo, will be part of a fireside chat. The event will focus on finding value in (Near-) Commercial Oncology Companies. PDS Biotech is a clinical-stage immunotherapy company developing cancer immunotherapies and infectious disease vaccines based on its proprietary T cell activating platforms.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.44%
Tags
conferences
News
PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
PDS Biotechnology Corporation (PDSB) granted 200,000 nonstatutory stock options to Lars Boesgaard, the new Chief Financial Officer. The stock option has an exercise price of $5.28 and vests over a four-year period, subject to continued employment with the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.76%
Tags
none
-
News
PDS Biotech Appoints Lars Boesgaard as Chief Financial Officer
Rhea-AI Summary
PDS Biotechnology Corporation (PDSB) announces the appointment of Lars Boesgaard as Chief Financial Officer, effective December 4, 2023. Boesgaard brings over 25 years of healthcare experience and has previously served as CFO of AM-Pharma B.V. and Columbia Care. He holds a Bachelor of Science in Business Administration from the Copenhagen Business School and a Master of Business Administration from the Richard Ivey School of Business, Western University, Ontario, Canada.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.66%
Tags
management
-
News
PDS Biotech Reports Third Quarter 2023 Financial Results and Provides Business Update
Rhea-AI Summary
PDS Biotechnology Corporation (Nasdaq: PDSB) announced positive results from multiple clinical trials, including a 75% survival rate at 36 months in the NCI-led Phase 2 combination trial for advanced HPV16-positive cancer patients, and a 74% 2-year overall survival rate in the VERSATILE-002 Phase 2 trial for HPV16-positive head and neck cancer patients. The company also reported promising interim safety and immune response data for a Phase 1/2 clinical trial for metastatic prostate cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.55%
Tags
earnings
News
PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of PDS0101-Based Triple Combination Therapy in Advanced HPV16-Positive Cancer Patients which Show 75% Survival of ICI Naïve Patients at 36 Months
Rhea-AI Summary
PDS Biotechnology Corporation (Nasdaq: PDSB) announced updated survival data from the Phase 2 clinical trial investigating the triple combination of PDS0101, PDS0301, and an investigational immune checkpoint inhibitor (ICI) in advanced cancer patients with HPV16-positive cancers. The trial showed 75% of ICI naïve patients remaining alive at 36 months, with a 12-month survival rate of 72% in ICI resistant patients. PDS0101 plus high doses of ICI and PDS0301 achieved an overall response rate of 63%, while the ORR for PDS0101 plus low doses of ICI and/or PDS0301 was 5%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.36%
Tags
clinical trial
Stock PDSB logo
PDS Biotechnology Corporation

Nasdaq:PDSB

PDSB Rankings

#4132 Ranked by Market Cap
#3526 Ranked by Stock Gains
N/A Ranked by Dividends

PDSB Stock Data

117.01M
35.41M
3.67%
22.93%
16.77%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Florham Park

About PDSB

pds biotechnology is a clinical stage biopharmaceutical company developing the next-generation of simpler, safer and more effective immunotherapies for cancer and infectious diseases. pds biotechnology’s proprietary versamune® platform vector is based on synthetic and biodegradable lipids which possess a very specific structure and positive charge. the lipids form nanoparticles which activate and are taken up very efficiently by the immune system. the therapeutic product consists of versamune® formulated with a harmless form of the protein or disease-causing agent associated with the particular disease (the antigen) which our immune systems can recognize and respond to. this antigen could be a unique protein expressed only in the cancer cells and not in healthy cells, or it could be a specific viral protein(s) from an infectious virus for example. pds is in the process of completing its first phase 1 human clinical trial in 2015 for pds0101, and has initiated design and preparati